Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
07 September 1984Website:
http://www.biomerica.comNext earnings report:
16 January 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | 14 min agoDividend
Analysts recommendations
Institutional Ownership
BMRA Latest News
IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the first quarter of fiscal 2025 ended August 31, 2024.
- 10-Minute At-Home PSA Test for Early Detection of Prostate Cancer - First order already shipped to Saudi Arabia - Prostate Cancer is the Second Most Common Cancer in Men Globally IRVINE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) is pleased to announce that the Saudi Food and Drug Authority (SFDA) has approved the Company's Fortel® Prostate (PSA) Screening Test to be sold and used in the country.
IRVINE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) today reported its financial results for the fiscal year ended May 31, 2024. The Company achieved a modest increase in net sales to $5.4 million, compared to $5.3 million in the prior year. This growth was primarily driven by strong demand for EZ Detect™ colorectal screening tests and Aware® breast self-exam products in the Middle East including the United Arab Emirates.
IRVINE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, is proud to announce a major enhancement to its inFoods® IBS system, aimed at simplifying and transforming the patient experience.
What type of business is Biomerica?
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops, markets, and sells COVID-19 diagnostic tests to indicate if a person has been infected by COVID-19. The company was incorporated in 1971 and is headquartered in Irvine, California.
What sector is Biomerica in?
Biomerica is in the Healthcare sector
What industry is Biomerica in?
Biomerica is in the Medical Devices industry
What country is Biomerica from?
Biomerica is headquartered in United States
When did Biomerica go public?
Biomerica initial public offering (IPO) was on 07 September 1984
What is Biomerica website?
https://www.biomerica.com
Is Biomerica in the S&P 500?
No, Biomerica is not included in the S&P 500 index
Is Biomerica in the NASDAQ 100?
No, Biomerica is not included in the NASDAQ 100 index
Is Biomerica in the Dow Jones?
No, Biomerica is not included in the Dow Jones index
When was Biomerica the previous earnings report?
No data
When does Biomerica earnings report?
The next expected earnings date for Biomerica is 16 January 2025